Imaging of endothelial progenitor cells and their role in tumor angiogenesis; Imaging of drug delivery and drug resistance; Molecular imaging
Dr. Dmitri Artemov is an Associate Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science and the Department of Oncology. He also serves as an Associate Director of the Cancer Functional Imaging Core, which provides dedicated molecular and functional imaging service to research funded by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He specializes in the development of molecular imaging technology to monitor drug delivery to tumors, drug release from tumor-targeted nanocarriers, and tumor response to therapy.
Dr. Artemov completed an M.S. in molecular physics at Moscow State University and received a Ph.D. in physics and mathematics from the Russian Academy of Sciences.
After postdoctoral fellowships in MR imaging and MR of cancer at the University of Wurzburg and Johns Hopkins, respectively, he joined the Johns Hopkins staff as an Instructor in the Department of Radiology in 1997 and became an Assistant Professor of Radiology in 1998. While working in that capacity, Artemov also completed an M.S. in biotechnology at Johns Hopkins. He became an Associate Professor of Radiology and Oncology in 2004.
Dr. Artemov is a member of the International Society for Magnetic Resonance in Medicine, the American Association for Cancer Research, and the Society for Molecular Imaging.
Ph.D., Institute of Chemical Physics (Unknown) (1991)
Institute of Chemical Physics, Moscow, Russia,, 1988, Fellow; Institute of Chemical Physics and Service Center Bruker,, Moscow, Russia, 1991, Scientist; Dept. of Radiology, Johns Hopkins University, Baltimore, MD, 1998, Instructor; The Johns Hopkins University, Baltimore, MD, 1997, MR of Cancer; University of Wurzburg, Germany, Wurzburg, Germany, 1992, MR Imaging
Dr. Artemov’s main research focus lies in the development of novel molecular imaging methods for highly sensitive and specific MR imaging of molecular targets. Using a combination of MRI and PET capabilities, he seeks to develop targeted theranostic agents and new methods for imaging of infiltrating progenitor cells in the context of tumor microenvironment.
Cancer Functional Imaging Core
Onuki Y, Jacobs I, Artemov D, Kato Y. "Noninvasive visualization of in vivo release and intratumoral distribution of surrogate MR contrast agent using the dual MR contrast technique." Biomaterials. 2010 Sep; 31(27): 7132-8. PMCID: PMC2917222.
Kato Y, Artemov D. "Monitoring of release of cargo from nanocarriers by MRI/MR spectroscopy (MRS): significance of T2/T2* effect of iron particles." Magn Reson Med. 2009 May; 61(5):1059-65. PMCID: PMC2718565.
Zhu W, Okollie B, Artemov D. "Controlled internalization of her-2/neu receptors by cross-linking for targeted delivery." Cancer Biol Ther. 2007 Dec; 6(12), 1960-6.
Raman V, Artemov D, Pathak AP, Winnard PT Jr, McNutt S, Yudina A, Bogdanov A, Bhujwalla ZM. "Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model." Cancer Res. 2006; 66(20): 9929-36.
Mironchik Y, Winnard PT Jr, Vesuna F, Kato Y, Wildes F, Pathak AP, Kominsky S, Artemov D, Bhujwalla Z, Van Diest P, Burger H, Glackin C, Raman V. "Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer." Cancer Res. 2005 Dec 1; 65(23):10801-9.